Navigation Links
Therapeutic prospects beyond Vioxx

Researchers at the University of Pennsylvania School of Medicine have clarified the mechanism by which drugs like Celebrex and Vioxx cause heart problems, in multiple animal models. The findings offer the prospect of a new generation of anti-inflammatory drugs that bypass this issue, as reported in the April 13 advanced online edition and May print issue of The Journal of Clinical Investigation.

"Although these results are in mice, not people, they raise an exciting possibility which can be tested in humans," says senior author Garret FitzGerald, MD, Director of Penn's Institute for Translational Medicine and Therapeutics,

Ever since the association of selective inhibitors of COX-2 ?Vioxx, Bextra, and Celebrex ?with an increased incidence of heart attack and stroke, there has been intense interest in understanding the mechanism involved. Clarification of this issue offers the prospect of conserving the clinical benefit of these drugs for patients with arthritis, while managing the risk.

Almost 10 years ago, FitzGerald noticed that both Celebrex and Vioxx depressed in healthy individuals a protective fat called prostacyclin, while leaving unaltered a harmful one called thromboxane. This led him to predict that drugs in this class might confer a cardiovascular risk before either reached the US market.

In the present studies, the investigators used multiple genetically manipulated mice ?including mice that mimicked the impact of either COX-2 inhibitors or low-dose aspirin and compared them with treating healthy mice with COX-2 inhibitors, such as Celebrex. They found that genetic disruption of COX-2; inhibition of the enzyme by different inhibitors; and disruption of prostacyclin's effects by removing its receptor all had the same effect ?a predisposition to clotting and an elevation of blood pressure. "This provides compelling evidence in support of the original hypothesis," says co-author Colin Funk, PhD, who has collaborated with Fit
'"/>

Source:University of Pennsylvania School of Medicine


Page: 1 2 3

Related biology news :

1. New Therapeutic Target Identified In Inherited Brain Tumor Disorder
2. Therapeutic role found for carbon monoxide
3. Protease inhibitors reach beyond HIV
4. NC State researchers redesign life for Mars and beyond
5. New classification of eukaryotes has implications for AIDS treatment, agriculture and beyond
6. Avian influenza virus in mammals spreads beyond the site of infection to other organ systems
7. Rotavirus can spread beyond the intestine
8. Parasites impact goes beyond host to affect ecosystem
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Therapeutic prospects beyond Vioxx

(Date:3/21/2010)... release is available in <A HREF=",http://chinese.eurekalert.org/zh/emb_releases/2010-03/asu-etb031810.php,">Chinese . ... debate in the U.S. Congress to ban the ... growing global environmental problem even worse, say authors ... Science and Technology appearing online today. , ... trade bans can prevent "backyard recycling" of electronics ...
(Date:3/21/2010)... Technology (Caltech)-led team of researchers and clinicians has ... as an experimental therapeutic and injected directly into ... small interfering RNAs (siRNAs), and turn off an ... RNA interference (RNAi). Moreover, the team provided the ... infused into the bloodstream, can make its way ...
(Date:3/18/2010)... for twenty years, fertilizing millions of eggs with sperm stored ... researchers who have studied ants at the Smithsonian Tropical Research ... and bee species in which queens have multiple mates, a ... over the other males, sperm. However, once sperm has been ...
Breaking Biology News(10 mins):E-waste trade ban won't end environmental threat 2Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 2Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 3Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 4Females shut down male-male sperm competition in leafcutter ants 2Nearly 100 HIV AIDS Drugs and Vaccines in Development Pipeline 6904 1Nearly 100 HIV AIDS Drugs and Vaccines in Development Pipeline 6904 2Alcohol consumption may increase breast cancer recurrence risk 63050 1Alcohol consumption may increase breast cancer recurrence risk 63050 2Synthetic protein mimics structure function of metalloprotein in nature 11087 1Synthetic protein mimics structure function of metalloprotein in nature 11087 2
... a naturally occurring toxin called Glycoalkaloids (GA) and pose a ... in the latest online issue of SCI,s Journal of ... the good news is that cutting away the ,green, affected ... reduce the risk. , The paper also suggests that ...
... Massachusetts General Hospital (MGH) investigators has developed a powerful ... robust method for generating synthetic enzymes that can target ... In the July 25 issue of Molecular Cell, ... to engineer customized zinc-finger nucleases (ZFNs), which can be ...
... inside the Arctic Circle, scientists have found black smoker vents ... of five vents one towering nearly four stories in ... Dissolved sulfide minerals that solidify when vent water hits the ... accumulated around the vent field in what is one of ...
Other Biology News:Consortium develops new method enabling routine targeted gene modification 2Scientists break record by finding northernmost hydrothermal vent field 2Scientists break record by finding northernmost hydrothermal vent field 3
(Date:3/18/2010)... Regenerative ... ... Cell Therapy Group is pleased to formally announce the addition of three new team ... Director, Stem Cell & Medical Device Business, and John E. Hambor, PhD as Director, ...
(Date:3/17/2010)... that Nano Research , an English-language journal jointly published ... the Science Citation Index-Expanded (SCI-E). The academic journal, founded ... Volume 1, Issue 1. Nano Research is part ... than 90 journals. , Nano Research is an ...
(Date:3/17/2010)... ,,, BALTIMORE , March 17 Champions Biotechnology, Inc. (OTC Bulletin Board: ... to enhance the value of oncology drugs, today announced its financial results for the third ... available in the Company,s Form 10-Q at www.championsbiotechnology.com . , ... ...
(Date:3/17/2010)... /PRNewswire-FirstCall/ - Æterna Zentaris Inc. ( AEZS, TSX: AEZ) (the "Company"), a late-stage ... and full year 2009 financial and operating results before market open on ... webcast to discuss these results later that same day at 10:00 a.m., ... ...
Breaking Biology Technology:Cell Therapy Group Announces Expansion of Consultants Roster in Regenerative Medicine 2Cell Therapy Group Announces Expansion of Consultants Roster in Regenerative Medicine 3Cell Therapy Group Announces Expansion of Consultants Roster in Regenerative Medicine 4China's first open-access journal Nano Research listed in Science Citation Index 2Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 5Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 6Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 7Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results 8Æterna Zentaris to Announce Fourth Quarter Full Year 2009 Financial and Operating Results on March 24, 2010 2
... FRANCISCO, Calif., June 16 Anesiva,Inc. (Nasdaq: ANSV ... as,president, chief executive officer and a member of the ... succeeds John P. McLaughlin,who resigned as chief executive officer ... interests, while remaining a consultant to the,company., "Michael ...
... June 16 ,EnzySurge Ltd. (EnzySurge), a provider of ... the formation of its,Scientific Advisory Board (SAB) comprised ... in chronic wounds.,The Company named David Armstrong, DPM ... RN, FAAN, Joseph L. Mills, MD, PhD and ...
... Pharma, Inc., a privately-,held, specialty pharmaceutical company, announced ... A financing, which included investors Domain Associates,Latterell Venture ... is committed to the development of prescription,products based ... the unmet,needs of patients and their caregivers. Meritage ...
Other Biology Technology:Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors 2Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors 3EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 2EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 3EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 4Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing 2
Moue Serum 8-12 Weeks Old...
Human DCIR/CLEC4A Phycoerythrin MAb (Clone 216110)...
Recombinant Mouse Wnt-3a...
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
Biology Products: